DE69426031T2 - Verzweigte synthetische peptid konjugate - Google Patents

Verzweigte synthetische peptid konjugate

Info

Publication number
DE69426031T2
DE69426031T2 DE69426031T DE69426031T DE69426031T2 DE 69426031 T2 DE69426031 T2 DE 69426031T2 DE 69426031 T DE69426031 T DE 69426031T DE 69426031 T DE69426031 T DE 69426031T DE 69426031 T2 DE69426031 T2 DE 69426031T2
Authority
DE
Germany
Prior art keywords
synthetic peptide
diagnostic
branched synthetic
peptide conjugates
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426031T
Other languages
English (en)
Other versions
DE69426031D1 (de
Inventor
Jean Gariepy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network Toronto Ontario Ca
Original Assignee
Ontario Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontario Cancer Institute filed Critical Ontario Cancer Institute
Publication of DE69426031D1 publication Critical patent/DE69426031D1/de
Application granted granted Critical
Publication of DE69426031T2 publication Critical patent/DE69426031T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/29—Polyamino acid or polypeptide with an uninterrupted series of peptide repeating units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69426031T 1994-06-09 1994-07-22 Verzweigte synthetische peptid konjugate Expired - Fee Related DE69426031T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/257,307 US5674977A (en) 1993-02-05 1994-06-09 Branched synthetic peptide conjugate
PCT/CA1994/000405 WO1995033766A1 (en) 1994-06-09 1994-07-22 Branched synthetic peptide conjugate

Publications (2)

Publication Number Publication Date
DE69426031D1 DE69426031D1 (de) 2000-11-02
DE69426031T2 true DE69426031T2 (de) 2001-05-10

Family

ID=22975740

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426031T Expired - Fee Related DE69426031T2 (de) 1994-06-09 1994-07-22 Verzweigte synthetische peptid konjugate

Country Status (6)

Country Link
US (1) US5674977A (de)
EP (1) EP0764170B1 (de)
AT (1) ATE196638T1 (de)
CA (1) CA2191862C (de)
DE (1) DE69426031T2 (de)
WO (1) WO1995033766A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
CN1215404A (zh) * 1996-04-03 1999-04-28 佩普里瑟奇公司 非树状骨架肽载体
GB9723825D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Nuclear targeting by means of bacterial proteins
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
EP1135410B1 (de) 1998-11-13 2008-12-31 Cyclacel Limited Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (de) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Spezifische bindungsproteine und ihre verwendung
IL158569A0 (en) * 2002-06-29 2004-05-12 Aquanova Ger Solubilisate Tech Isoflavone concentrates and methods for the production thereof
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
CA2692240C (en) 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9095624B2 (en) 2011-05-23 2015-08-04 Contango Partners Group, Inc. Modular transport platform for targeted delivery of therapeutic agents
MX2015006109A (es) 2012-11-15 2016-02-05 Endocyte Inc Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
ES2722924T3 (es) * 2012-12-05 2019-08-20 Univ Heidelberg Ruprecht Karls Conjugados de proteínas y péptidos multivalentes de penetración celular y sus usos
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20190134231A1 (en) * 2016-04-21 2019-05-09 The Board Of Regents Of The University Of Texas System Methods and compositions for detecting aneurysms
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US4645661A (en) * 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0339695A3 (de) * 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen Verfahren zur Herstellung eines antigenen bzw. immunogenen Konjugats sowie die Verwendung solcher Konjugate
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5368712A (en) * 1989-11-02 1994-11-29 Synporin Technologies, Inc. Biologically mimetic synthetic ion channel transducers
ATE154609T1 (de) * 1990-10-15 1997-07-15 Tecnogen Scpa Nicht-lineare peptide, die hydropatisch komplementär zu bekannten aminosäuresequenzen sind, verfahren zur herstellung und verwendung davon
WO1992009893A1 (en) * 1990-11-29 1992-06-11 Carbaugh John E DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a)
WO1993003766A1 (en) * 1991-08-13 1993-03-04 Repligen Corporation Multiple antigen peptides for use as hiv vaccines
CA2094785A1 (en) * 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus

Also Published As

Publication number Publication date
US5674977A (en) 1997-10-07
CA2191862C (en) 1999-12-28
DE69426031D1 (de) 2000-11-02
WO1995033766A1 (en) 1995-12-14
EP0764170A1 (de) 1997-03-26
ATE196638T1 (de) 2000-10-15
CA2191862A1 (en) 1995-12-14
EP0764170B1 (de) 2000-09-27

Similar Documents

Publication Publication Date Title
DE69426031T2 (de) Verzweigte synthetische peptid konjugate
ES2492670T3 (es) Análogos peptídicos de la hormona estimulante de alfa-melanocitos
DK66391A (da) Terapeutisk virksomme peptider
ES2232941T3 (es) Compuestos y metodos para inhibir la interaccion entre alfa-catenina y beta-catenina.
ES2053757T3 (es) Composiciones inhibidoras de fosfolipasa a2 y su uso.
PL186341B1 (pl) Oligopeptyd, sposób oznaczania aktywności proteolitycznej wolnego antygenu swoistego dla prostaty wpróbce, sposób identyfikacji związków, hamującychaktywność proteolityczną antygenu swoistego dla prostaty, oraz koniugat użyteczny do leczenia raka prostaty
DK269284D0 (da) Syntetisk peptid, der paavirker hypofysekirtelens funktion
US20020155565A1 (en) FAP-activated anti-tumor compounds
WO2005105029A1 (es) Uso de péptidos xikvav en preparación de composiciones cosméticas para mejorar la firmeza de la piel mediante el aumento de la adhesión celular
KR100580137B1 (ko) 전립선 암 치료에 유용한 접합체 및 이를 포함하는 약제학적 조성물
ATE547709T1 (de) Tumorinvasionsfördernde peptidsequenz
BR9812963A (pt) Análogos de sarcodictina e eleuterobina
US6451969B1 (en) Methods for inhibiting tumor metastasis, and peptides useful therfor
NO974750L (no) Peptid antagonister av cellulær mitogenese og motogenese og deres terapautiske anvendelse
CA2242750A1 (en) Antibodies with reduced net positive charge
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
IE782423L (en) Tetrapeptide segment
JP5138680B2 (ja) 増殖抑制作用を有するペプチド
DE68923613D1 (de) Superoxid-dismutaseanaloge mit neuen bindeeigenschaften.
Maletínskâ et al. Lipid masking and reactivation of angiotensin analogues
Faircloth et al. Biological activity of thiocoraline, a novel marine depsipeptide
Talwar et al. Spatial Vectorcardiography in the Wolff‐Parkinson‐White Syndrome: Correlation with Epicardial Mapping Findings
Smythies Hypotheses on the molecular mechanism of action of tumor promoters
WO1998020887A1 (en) Polyphosphoinositide binding peptides for intracellular drug delivery
CA2277011A1 (en) Membrane-permeable derivatives converted intracellularly into active peptides

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITY HEALTH NETWORK, TORONTO, ONTARIO, CA

8339 Ceased/non-payment of the annual fee